LG Life Sciences, Ltd. - Product Pipeline Review - 2014

Published: Jul, 2014 | Pages: 68 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

LG Life Sciences, Ltd. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'LG Life Sciences, Ltd. - Product Pipeline Review - 2014', provides an overview of the LG Life Sciences, Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of LG Life Sciences, Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of LG Life Sciences, Ltd. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of LG Life Sciences, Ltd.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the LG Life Sciences, Ltd.'s pipeline products

Reasons to buy

- Evaluate LG Life Sciences, Ltd.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of LG Life Sciences, Ltd. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the LG Life Sciences, Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of LG Life Sciences, Ltd. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of LG Life Sciences, Ltd.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of LG Life Sciences, Ltd. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 6
LG Life Sciences, Ltd. Snapshot 7
LG Life Sciences, Ltd. Overview 7
Key Information 7
Key Facts 7
LG Life Sciences, Ltd. - Research and Development Overview 8
Key Therapeutic Areas 8
LG Life Sciences, Ltd. - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
Pipeline Products - Combination Treatment Modalities 13
Pipeline Products - Partnered Products 14
Partnered Products/Combination Treatment Modalities 15
Pipeline Products - Out-Licensed Products 16
Out-Licensed Products/Combination Treatment Modalities 17
LG Life Sciences, Ltd. - Pipeline Products Glance 18
LG Life Sciences, Ltd. - Late Stage Pipeline Products 18
Pre-Registration Products/Combination Treatment Modalities 18
Phase III Products/Combination Treatment Modalities 19
LG Life Sciences, Ltd. - Clinical Stage Pipeline Products 20
Phase II Products/Combination Treatment Modalities 20
Phase I Products/Combination Treatment Modalities 21
LG Life Sciences, Ltd. - Early Stage Pipeline Products 22
Preclinical Products/Combination Treatment Modalities 22
Discovery Products/Combination Treatment Modalities 23
LG Life Sciences, Ltd. - Unknown Stage Pipeline Products 24
Unknown Products/Combination Treatment Modalities 24
LG Life Sciences, Ltd. - Drug Profiles 25
somatropin SR 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
(gemigliptin + metformin hydrochloride) 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
(gemigliptin + rosuvastatin) 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
DtwP-HB-Hib (liq) Vaccine 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
(lercanidipine hydrochloride + valsartan) 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
interferon alfa-2a SR 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
LC-280126 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
LD-02GIFRO 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
nivocasan 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
(gemigliptin + sulfonylureas) 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
etanercept biosimilar 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
LC-231306 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
LC-350189 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
infliximab biosimilar 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
LBFL-0101 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
LC-280391 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
LC-51SPA 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
NecX 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
rituximab biosimilar 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Small Molecules For Obesity 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
exenatide SR 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
LBBZ 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
LC-34AD3 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
LC-52CIS 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
LC-53LEOH 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
LC-54AID3 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Small Molecule To inhibit PAR-1 for Atherothrombosis 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Monoclonal Antibody to Inhibit VEGF for Cancer 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
LG Life Sciences, Ltd. - Pipeline Analysis 57
LG Life Sciences, Ltd. - Pipeline Products by Target 57
LG Life Sciences, Ltd. - Pipeline Products by Route of Administration 59
LG Life Sciences, Ltd. - Pipeline Products by Molecule Type 60
LG Life Sciences, Ltd. - Pipeline Products by Mechanism of Action 61
LG Life Sciences, Ltd. - Recent Pipeline Updates 63
LG Life Sciences, Ltd. - Dormant Projects 64
LG Life Sciences, Ltd. - Locations And Subsidiaries 65
Head Office 65
Other Locations & Subsidiaries 65
Appendix 67
Methodology 67
Coverage 67
Secondary Research 67
Primary Research 67
Expert Panel Validation 67
Contact Us 68
Disclaimer 68

List of Tables
LG Life Sciences, Ltd., Key Information 7
LG Life Sciences, Ltd., Key Facts 7
LG Life Sciences, Ltd. - Pipeline by Indication, 2014 9
LG Life Sciences, Ltd. - Pipeline by Stage of Development, 2014 11
LG Life Sciences, Ltd. - Monotherapy Products in Pipeline, 2014 12
LG Life Sciences, Ltd. - Combination Treatment Modalities in Pipeline, 2014 13
LG Life Sciences, Ltd. - Partnered Products in Pipeline, 2014 14
LG Life Sciences, Ltd. - Partnered Products/ Combination Treatment Modalities, 2014 15
LG Life Sciences, Ltd. - Out-Licensed Products in Pipeline, 2014 16
LG Life Sciences, Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2014 17
LG Life Sciences, Ltd. - Pre-Registration, 2014 18
LG Life Sciences, Ltd. - Phase III, 2014 19
LG Life Sciences, Ltd. - Phase II, 2014 20
LG Life Sciences, Ltd. - Phase I, 2014 21
LG Life Sciences, Ltd. - Preclinical, 2014 22
LG Life Sciences, Ltd. - Discovery, 2014 23
LG Life Sciences, Ltd. - Unknown, 2014 24
LG Life Sciences, Ltd. - Pipeline by Target, 2014 58
LG Life Sciences, Ltd. - Pipeline by Route of Administration, 2014 59
LG Life Sciences, Ltd. - Pipeline by Molecule Type, 2014 60
LG Life Sciences, Ltd. - Pipeline Products by Mechanism of Action, 2014 62
LG Life Sciences, Ltd. - Recent Pipeline Updates, 2014 63
LG Life Sciences, Ltd. - Dormant Developmental Projects,2014 64
LG Life Sciences, Ltd., Other Locations 65
LG Life Sciences, Ltd., Subsidiaries 66